AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31337122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tart Cherry Juice (TC)
Number of subjects: 36
Study 31337122 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice (POM)
Number of subjects: 36
Study 31337122 — intervention group
Group type: COMPARATOR
Intervention: Energy-matched fruit-flavored placebo drink
Number of subjects: 36
Study 30478021 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CT (mobile cognitive therapy) with minimal therapist support added to treatment as usual (TAU)
Number of subjects: 264
Study 30478021 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 264
Study 27370526 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted SBIRT
Number of subjects: 572
Study 27370526 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted education program on nutrition (control)
Number of subjects: 572
Study 25486369 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline B12 concentrations (148 to 221 pmol/L)
Number of subjects: 103
Study 25486369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low B12 (<148 pmol/L)
Number of subjects: 103
Study 25486369 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal B12 concentrations (not specified)
Number of subjects: 103
Study 22475985 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine plus ultra-low-dose naloxone (0.3 mg + 0.02 mg)
Number of subjects: 12
Study 22475985 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine alone (0.3 mg)
Number of subjects: 12
Study 20532452 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg orally one hour prior to imaging
Number of subjects: 96
Study 20532452 — intervention group
Group type: COMPARATOR
Intervention: Lemon juice (standard of care)
Number of subjects: 96
Study 16234574 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 40 KHz ultrasound therapy delivered by a saline mist
Number of subjects: 55
Study 16234574 — intervention group
Group type: COMPARATOR
Intervention: Sham device delivering saline mist without ultrasound
Number of subjects: 55
Study 12399142 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine (0.3 mg/kg; intravenous)
Number of subjects: 18
Study 12399142 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol (2 mg) + ketamine (0.3 mg/kg; intravenous)
Number of subjects: 18
Study 12399142 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 11725662 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesively bonded amalgam restorations using ED Primer and Panavia 21 TC
Number of subjects: 31
Study 11725662 — intervention group
Group type: COMPARATOR
Intervention: Non-bonded amalgam restorations
Number of subjects: 31
Study 7572966 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine for Haemophilus influenzae type b (Hib)
Number of subjects: 0
Study 2301090 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (Seloken) administered once or twice daily
Number of subjects: 303
Study 2301090 — intervention group
Group type: EXPERIMENTAL
Intervention: General Health Questionnaire (GHQ)
Number of subjects: 303
Study 2301090 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 303
Study 6993207 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐sulphur colloid
Number of subjects: 0
Study 6993207 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐tin colloid
Number of subjects: 0
Study 6993207 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc phytate colloid
Number of subjects: 0
Study 31543373 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (2 g, ×2)
Number of subjects: 34
Study 31543373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil, 2 g ×2)
Number of subjects: 34
Study 31543373 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA
Number of subjects: 34
Study 31543373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31024122 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced receptor type‐specific actions of dopamine in women
Number of subjects: 0
Study 31024122 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced receptor type‐specific actions of dopamine in men
Number of subjects: 0
Study 31024122 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural reward system activity during prosocial decisions
Number of subjects: 0
Study 25870186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 22
Study 25870186 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 22
Study 25870186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 22
Study 25870186 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 22
Study 23812551 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-supplemented enteral nutrition (9.0 g/L)
Number of subjects: 73
Study 23812551 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition
Number of subjects: 73
Study 21367943 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (20 g)
Number of subjects: 48
Study 21367943 — intervention group
Group type: COMPARATOR
Intervention: Casein (20 g)
Number of subjects: 48
Study 21367943 — intervention group
Group type: COMPARATOR
Intervention: Casein hydrolysate (20 g)
Number of subjects: 48
Study 19737620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 mcg) once daily
Number of subjects: 676
Study 19737620 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium (26 mcg)/Albuterol (206 mcg), 2 actuations 4 times daily
Number of subjects: 676
Study 17403721 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP) levels in diabetic patients vs. non-diabetic patients in OPUS-TIMI 16 (9 mg/L vs. 7.8 mg/L, P = 0.002)
Number of subjects: 2200
Study 17403721 — intervention group
Group type: COMPARATOR
Intervention: MCP-1 levels in diabetic patients vs. non-diabetic patients in OPUS-TIMI 16 (190.6 pg/mL vs. 170.8 pg/mL, P = 0.04)
Number of subjects: 2200
Study 17403721 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein levels in diabetic patients vs. non-diabetic patients in TACTICS-TIMI 18 (6.6 mg/L vs. 5.2 mg/L, P = 0.0005)
Number of subjects: 2200
Study 17403721 — intervention group
Group type: COMPARATOR
Intervention: Risk associated with C-reactive protein greater than or equal to the median in diabetic patients vs. non-diabetic patients in OPUS-TIMI 16 (adjusted HR 1.63, 95% CI 1.20-2.23, P = 0.002)
Number of subjects: 2200
Study 17403721 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk associated with a 1 mmol/L increase in glucose among those with CRP greater than or equal to the median (HR 1.07, 95% CI 1.03-1.11) vs. those with CRP less than the median (HR 1.02, 95% CI 0.97-1.06)
Number of subjects: 2200
Study 17403721 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergistic relationship between glucose and C-reactive protein on clinical outcomes
Number of subjects: 2200
Study 15110367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.015 mg.k(‐1)
Number of subjects: 90
Study 15110367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.09 mg.k(‐1)
Number of subjects: 90
Study 15110367 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 90
Study 11255446 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/d
Number of subjects: 763
Study 11255446 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/d followed by 10 mg/d
Number of subjects: 763
Study 11255446 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 763
Study 11255446 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after 6-week washout)
Number of subjects: 763
Study 11255446 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 763
Study 9398110 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 40
Study 9398110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8423906 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice a day
Number of subjects: 603
Study 8423906 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 650 mg twice a day
Number of subjects: 603
Study 3122887 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim discharge summary delivered by hand
Number of subjects: 289
Study 3122887 — intervention group
Group type: COMPARATOR
Intervention: Interim discharge summary posted by the hospital
Number of subjects: 289
Study 29524451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 16
Study 29524451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27260219 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP with Kinesio Textape
Number of subjects: 10
Study 27260219 — intervention group
Group type: COMPARATOR
Intervention: CDP with bandage
Number of subjects: 10
Study 24731498 — intervention group
Group type: EXPERIMENTAL
Intervention: No antibiotics (n = 192)
Number of subjects: 326
Study 24731498 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics (n = 134)
Number of subjects: 326
Study 23886062 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-sided news coverage (positive and negative information)
Number of subjects: 0
Study 23886062 — intervention group
Group type: COMPARATOR
Intervention: 1-sided news coverage (unanimously positive information)
Number of subjects: 0
Study 20588187 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/h transdermal nitroglycerin (TGTN)
Number of subjects: 30
Study 20588187 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/h transdermal nitroglycerin (TGTN)
Number of subjects: 30
Study 20588187 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nitroglycerin and inhaled salbutamol
Number of subjects: 30
Study 18841285 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose (LD) / 10 mg maintenance dose (MD)
Number of subjects: 110
Study 18841285 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg loading dose (LD) / 75 mg maintenance dose (MD)
Number of subjects: 110
Study 16631056 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof Natural intraocular lens (SN60AT)
Number of subjects: 13
Study 16631056 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof intraocular lens (SA60AT)
Number of subjects: 13
Study 14583122 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic virtual environments derived from computer games (TVEDG)
Number of subjects: 26
Study 14583122 — intervention group
Group type: COMPARATOR
Intervention: Non-phobic control participants
Number of subjects: 26
Study 11371659 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunoadsorption and intravenous immunoglobulins (n=17)
Number of subjects: 35
Study 11371659 — intervention group
Group type: COMPARATOR
Intervention: Immunoadsorption alone (Control group, n=18)
Number of subjects: 35
Study 11371659 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of immunoglobulins at a dose of 0.14 g/kg
Number of subjects: 35
Study 11371659 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin administration
Number of subjects: 35
Study 9236347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepid temperature (34 degrees C)
Number of subjects: 18
Study 9236347 — intervention group
Group type: COMPARATOR
Intervention: Moderate hypothermia (28 degrees C)
Number of subjects: 18
Study 7963604 — intervention group
Group type: EXPERIMENTAL
Intervention: Single layer mass closure with monofilament nylon
Number of subjects: 160
Study 7963604 — intervention group
Group type: COMPARATOR
Intervention: Layer closure with chromic catgut
Number of subjects: 160
Study 2956870 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (MDL 17,043) 50, 75, 100, 150 or 200 mg (mean dose 1.46 +/- 0.16 mg/kg)
Number of subjects: 14
Study 2956870 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (MDL 17,043)
Number of subjects: 14
Study 30037519 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV with nasal cannula (NC) at 15 L/min of oxygen
Number of subjects: 37
Study 30037519 — intervention group
Group type: COMPARATOR
Intervention: NIPPV alone
Number of subjects: 37
Study 27904973 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4-metabolized statins (group A, n=725)
Number of subjects: 1187
Study 27904973 — intervention group
Group type: COMPARATOR
Intervention: Non-CYP3A4-metabolized statins (group B, n=462)
Number of subjects: 1187
Study 27904973 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4-metabolized statins (group A, n=725) with high baseline PRU
Number of subjects: 1187
Study 27904973 — intervention group
Group type: COMPARATOR
Intervention: Non-CYP3A4-metabolized statins (group B, n=462) with high baseline PRU
Number of subjects: 1187
Study 27904973 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4-metabolized statins and non-CYP3A4-metabolized statins
Number of subjects: 1187
Study 25818472 — intervention group
Group type: EXPERIMENTAL
Intervention: DSMS program
Number of subjects: 403
Study 25818472 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 403
Study 23690996 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity-based treatment protocols
Number of subjects: 22
Study 23690996 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (specific gene expression profiling)
Number of subjects: 22
Study 21698485 — intervention group
Group type: EXPERIMENTAL
Intervention: Women after standard TKA
Number of subjects: 494
Study 21698485 — intervention group
Group type: COMPARATOR
Intervention: Men after standard TKA
Number of subjects: 494
Study 21698485 — intervention group
Group type: EXPERIMENTAL
Intervention: Women and Men after standard TKA
Number of subjects: 494
Study 18277832 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's‐only motivational interviewing
Number of subjects: 182
Study 18277832 — intervention group
Group type: COMPARATOR
Intervention: Traditional CR group
Number of subjects: 182
Study 17138506 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity score analysis
Number of subjects: 0
Study 17138506 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 17138506 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical techniques
Number of subjects: 0
Study 17138506 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic techniques
Number of subjects: 0
Study 12925845 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAM1000
Number of subjects: 0
Study 12925845 — intervention group
Group type: COMPARATOR
Intervention: Dryvax
Number of subjects: 0
Study 10615845 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma beta-carotene levels (quintiles)
Number of subjects: 987
Study 10615845 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma alpha-tocopherol levels
Number of subjects: 987
Study 10615845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no respiratory symptoms)
Number of subjects: 987
Study 9411502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy (0.4 mg/kg every 12 hours for 2 days, started 10 minutes before the first antibiotic dose)
Number of subjects: 151
Study 9411502 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid treated patients
Number of subjects: 151
Study 9411502 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bacterial meningitis
Number of subjects: 151
Study 9411502 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients with meningitis
Number of subjects: 151
Study 9411502 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased production of NO in the CSF compartment during the acute phase of BM
Number of subjects: 151
Study 31718683 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder-Café intervention
Number of subjects: 120
Study 31718683 — intervention group
Group type: COMPARATOR
Intervention: Shoulder-Guidance intervention (active control)
Number of subjects: 120
Study 28770549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sono-electro-magnetic therapy
Number of subjects: 0
Study 28770549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26600173 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min long 2.4 GHz Wi-Fi exposure
Number of subjects: 25
Study 24580570 — intervention group
Group type: EXPERIMENTAL
Intervention: PMTO (n=51)
Number of subjects: 102
Study 24580570 — intervention group
Group type: COMPARATOR
Intervention: Community services (n=51)
Number of subjects: 102
Study 21385862 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day of rosuvastatin added to 80 mg/day of valsartan (ARB)
Number of subjects: 124
Study 21385862 — intervention group
Group type: COMPARATOR
Intervention: ARB monotherapy (80 mg/day of valsartan)
Number of subjects: 124
Study 18703220 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time meeting with a psychologist discussing issues and concerns about cancer diagnosis
Number of subjects: 100
Study 18703220 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 100
Study 18703220 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time meeting with a psychologist
Number of subjects: 100
Study 15936063 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (muscarinic antagonism)
Number of subjects: 12
Study 15936063 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (nicotinic antagonism)
Number of subjects: 12
Study 15936063 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine + Scopolamine (simultaneous antagonism)
Number of subjects: 12
Study 15936063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study 11753134 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic strategies other than antimicrobials for urinary tract infection management in postmenopausal women due to vaginal estrogen deficiency.
Number of subjects: 0
Study 11753134 — intervention group
Group type: COMPARATOR
Intervention: Management of clinical deterioration in long-term care facility residents with positive urine cultures.
Number of subjects: 0
Study 11753134 — intervention group
Group type: COMPARATOR
Intervention: Urine culture as a diagnostic tool.
Number of subjects: 0
Study 10695503 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict bed rest for 8 days
Number of subjects: 126
Study 10695503 — intervention group
Group type: COMPARATOR
Intervention: Mobilised (control group)
Number of subjects: 126
Study 8690778 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog and monkey sera used as blocking antibodies against mouse anti-hsCR1 monoclonal antibodies
Number of subjects: 0
Study 8690778 — intervention group
Group type: EXPERIMENTAL
Intervention: Human sera (blood group antisera: anti-Knops, anti-McCoy, anti-Knops/McCoy, anti-Swain-Langley)
Number of subjects: 0
Study 8690778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse, rat, dog antibodies
Number of subjects: 0
Study 8690778 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCR1
Number of subjects: 0
Study 1930618 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 4 mg
Number of subjects: 26
Study 1930618 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 6 mg
Number of subjects: 26
Study 1930618 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group REM-P)
Number of subjects: 26
Study 1930618 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (Group REM-Bip)
Number of subjects: 26
Study 7049075 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical poly(ICLC)
Number of subjects: 57
Study 7049075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 31335937 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 0
Study 31335937 — intervention group
Group type: EXPERIMENTAL
Intervention: All protein targets
Number of subjects: 0
Study 31335937 — intervention group
Group type: EXPERIMENTAL
Intervention: Without consideration of the protein targets
Number of subjects: 0
Study 31698659 — intervention group
Group type: EXPERIMENTAL
Intervention: AFO (Ankle-Foot Orthosis) fabricated using material PA12
Number of subjects: 12
Study 31698659 — intervention group
Group type: COMPARATOR
Intervention: No AFO (Control)
Number of subjects: 12
Study 26548697 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Sinuplasty
Number of subjects: 0
Study 26548697 — intervention group
Group type: COMPARATOR
Intervention: Uncinectomy
Number of subjects: 0
Study 25079920 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Practice Care (BPC)
Number of subjects: 271
Study 25079920 — intervention group
Group type: COMPARATOR
Intervention: Motivational Interviewing (MI)
Number of subjects: 271
Study 25079920 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recall
Number of subjects: 271
Study 25079920 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education
Number of subjects: 271
Study 25079920 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental ratings of usefulness of information
Number of subjects: 271
Study 22271474 — intervention group
Group type: EXPERIMENTAL
Intervention: T-BEP (paclitaxel-bleomycin, etoposide, and cisplatin)
Number of subjects: 337
Study 22271474 — intervention group
Group type: COMPARATOR
Intervention: BEP (bleomycin, etoposide, and cisplatin)
Number of subjects: 337
Study 20391735 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 mg/kg and Propofol 2 mg/kg (group PRO)
Number of subjects: 30
Study 20391735 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 mg/kg and Sevoflurane 5% in a 1:2 mixture of oxygen and nitrous oxide (group SEVO)
Number of subjects: 30
Study 18165765 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous alemtuzumab (30 mg doses on days 0 and 1)
Number of subjects: 21
Study 18165765 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous alemtuzumab
Number of subjects: 21
Study 15226321 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel plus thalidomide 200 mg orally each day
Number of subjects: 75
Study 15226321 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 30 mg/m(2) intravenously every week for 3 consecutive weeks
Number of subjects: 75
Study 11566519 — intervention group
Group type: EXPERIMENTAL
Intervention: LEC removal from the nasal half (Group B)
Number of subjects: 60
Study 11566519 — intervention group
Group type: EXPERIMENTAL
Intervention: LEC removal from the entire anterior capsule (Group C)
Number of subjects: 60